» Articles » PMID: 20884379

An ECG Index of Myocardial Scar Enhances Prediction of Defibrillator Shocks: an Analysis of the Sudden Cardiac Death in Heart Failure Trial

Overview
Journal Heart Rhythm
Publisher Elsevier
Date 2010 Oct 2
PMID 20884379
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Only a minority of patients receiving implantable cardioverter-defibrillators (ICDs) for the primary prevention of sudden death receive appropriate shocks, yet almost as many are subjected to inappropriate shocks and device complications. Identifying and quantifying myocardial scar, which forms the substrate for ventricular tachyarrhythmias, may improve risk stratification.

Objective: This study sought to determine whether the absence of myocardial scar detected by novel 12-lead electrocardiographic (ECG) Selvester QRS scoring criteria identifies patients with low risk for appropriate ICD shocks.

Methods: We applied QRS scoring to 797 patients from the ICD arm of the Sudden Cardiac Death in Heart Failure Trial. Patients were followed up for a median of 45.5 months for ventricular tachycardia/fibrillation treated by the ICD or sudden tachyarrhythmic death (combined group referred to as VT/VF).

Results: Increasing QRS score scar size predicted higher rates of VT/VF. Patients with no scar (QRS score = 0) represented a particularly low-risk cohort with 48% fewer VT/VF events than the rest of the population (absolute difference 11%; hazard ratio 0.52, 95% confidence interval 0.31 to 0.88). QRS score scar absence versus presence remained a significant prognostic factor after controlling for 10 clinically relevant variables. Combining QRS score (scar absence versus presence) with ejection fraction (≥ 25% versus < 25%) distinguished low-, middle-, and high-risk subgroups with 73% fewer VT/VF events in the low-risk versus high-risk group (absolute difference 22%; hazard ratio = 0.27, 95% confidence interval 0.12 to 0.62).

Conclusion: Patients with no scar by QRS scoring have significantly fewer VT/VF events. This inexpensive 12-lead ECG tool provides unique, incremental prognostic information and should be considered in risk-stratifying algorithms for selecting patients for ICDs.

Citing Articles

Ventricular Depolarization Abnormalities and Their Role in Cardiac Risk Stratification - A Narrative Review.

Blondeel M, Robyns T, Willems R, Vandenberk B Rev Cardiovasc Med. 2025; 26(1):25921.

PMID: 39867187 PMC: 11759958. DOI: 10.31083/RCM25921.


Arrhythmic sudden death survival prediction using deep learning analysis of scarring in the heart.

Popescu D, Shade J, Lai C, Aronis K, Ouyang D, Moorthy M Nat Cardiovasc Res. 2022; 1(4):334-343.

PMID: 35464150 PMC: 9022904. DOI: 10.1038/s44161-022-00041-9.


Selvester Score May Be a Predictor of ICD Therapies in Patients with Non-Ischemic Dilated Cardiomyopathy.

Kuyumcu M, Uzun M, Ozen Y, Aksoy F, Uysal B, Varol E Braz J Cardiovasc Surg. 2022; 37(6):900-907.

PMID: 35436074 PMC: 9713652. DOI: 10.21470/1678-9741-2021-0112.


Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study.

Pelli A, Junttila M, Kentta T, Schlogl S, Zabel M, Malik M Europace. 2021; 24(5):774-783.

PMID: 34849744 PMC: 9071070. DOI: 10.1093/europace/euab260.


Selvester score predicts implantable cardioverter defibrillator shocks in patients with non-ischemic cardiomyopathy.

Arisoy F, Celebi O, Erbay I, Tufekcioglu O, Aydogdu S, Temizhan A J Arrhythm. 2021; 37(4):1046-1051.

PMID: 34386131 PMC: 8339102. DOI: 10.1002/joa3.12571.


References
1.
Jones M, Anderson K, Wilson P, Kannel W, Wagner N, Wagner G . Prognostic use of a QRS scoring system after hospital discharge for initial acute myocardial infarction in the Framingham cohort. Am J Cardiol. 1990; 66(5):546-50. DOI: 10.1016/0002-9149(90)90479-k. View

2.
Packer D, Prutkin J, Hellkamp A, Mitchell L, Bernstein R, Wood F . Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009; 120(22):2170-6. PMC: 2922511. DOI: 10.1161/CIRCULATIONAHA.109.853689. View

3.
Reynolds M, Cohen D, Kugelmass A, Brown P, Becker E, Culler S . The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006; 47(12):2493-7. PMC: 1800827. DOI: 10.1016/j.jacc.2006.02.049. View

4.
Sweeney M, van Bommel R, Schalij M, Borleffs C, Hellkamp A, Bax J . Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation. 2010; 121(5):626-34. DOI: 10.1161/CIRCULATIONAHA.109.894774. View

5.
Myerburg R . Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008; 359(21):2245-53. DOI: 10.1056/NEJMra0803409. View